Cancer stem cells (CSCs) are a small population of cells within tumors that possess the ability to self-renew, drive tumor growth, and are believed to be responsible for relapse and metastasis. These cells are highly resistant to conventional therapies, which often fail to target the CSCs effectively. Tumor heterogeneity, the presence of diverse cell types within a single tumor, further complicates treatment strategies. Researchers are focusing on understanding the molecular characteristics that distinguish CSCs from normal stem cells and developing therapies that specifically target these cells. Overcoming the challenges posed by CSCs and tumor heterogeneity could significantly improve cancer treatment outcomes and reduce the likelihood of relapse.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China